AU2002226028A1 - Mutant human factor ix with an increased resistance to inhibition by heparin - Google Patents

Mutant human factor ix with an increased resistance to inhibition by heparin

Info

Publication number
AU2002226028A1
AU2002226028A1 AU2002226028A AU2602802A AU2002226028A1 AU 2002226028 A1 AU2002226028 A1 AU 2002226028A1 AU 2002226028 A AU2002226028 A AU 2002226028A AU 2602802 A AU2602802 A AU 2602802A AU 2002226028 A1 AU2002226028 A1 AU 2002226028A1
Authority
AU
Australia
Prior art keywords
heparin
inhibition
increased resistance
human factor
mutant human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002226028A
Inventor
John P. Sheehan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Board Of Regents Unversity Of Texas Systems
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of AU2002226028A1 publication Critical patent/AU2002226028A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
AU2002226028A 2000-11-14 2001-11-13 Mutant human factor ix with an increased resistance to inhibition by heparin Abandoned AU2002226028A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24832600P 2000-11-14 2000-11-14
US60/248,326 2000-11-14
PCT/US2001/047276 WO2002040544A2 (en) 2000-11-14 2001-11-13 Mutant human factor ix with an increased resistance to inhibition by heparin

Publications (1)

Publication Number Publication Date
AU2002226028A1 true AU2002226028A1 (en) 2002-05-27

Family

ID=22938622

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002226028A Abandoned AU2002226028A1 (en) 2000-11-14 2001-11-13 Mutant human factor ix with an increased resistance to inhibition by heparin

Country Status (3)

Country Link
US (1) US7125841B2 (en)
AU (1) AU2002226028A1 (en)
WO (1) WO2002040544A2 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
CA2463301A1 (en) * 2004-04-22 2005-10-22 Atanas Iliev Lalev Method for detecting protein interactions - affinity purification with switching the ligand
DK2380985T3 (en) 2003-09-23 2014-03-17 Univ North Carolina Cells expressing the vitamin K epoxide reductase, as well as their use
CA2557061C (en) * 2004-03-19 2013-08-20 Baxter International Inc. Factor ixa for the treatment of bleeding disorders
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
EP2084274A2 (en) 2006-06-19 2009-08-05 Nautilus Technology LLC Modified coagulation factor ix polypeptides and use thereof for treatment
US20080214462A1 (en) 2007-02-01 2008-09-04 Baxter International Inc. FIX-Mutant Proteins for Hemophilia B Treatment
EP2108046B9 (en) 2007-02-01 2014-03-26 Baxter International Inc. Fviii-independent fix-mutant proteins for hemophilia a treatment
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
CA2737094C (en) 2008-09-15 2018-02-20 Paolo Simioni Factor ix polypeptide mutant, its uses and a method for its production
AU2010290077C1 (en) 2009-08-24 2015-12-03 Bioverativ Therapeutics Inc. Coagulation factor IX compositions and methods of making and using same
AU2011274414B2 (en) 2010-07-09 2016-10-06 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
TWI595004B (en) 2010-11-03 2017-08-11 介控生化科技公司 Modified factor ix polypeptides and uses thereof
WO2012088222A2 (en) 2010-12-21 2012-06-28 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
EP2737311B1 (en) 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
WO2013122617A1 (en) 2012-02-15 2013-08-22 Amunix Operating Inc. Factor viii compositions and methods of making and using same
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
WO2014052490A1 (en) 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
PL3889173T3 (en) 2013-02-15 2023-12-11 Bioverativ Therapeutics Inc. Optimized factor viii gene
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
EP3082848B1 (en) 2013-12-06 2023-10-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
JP2017500017A (en) 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
AU2015236340B2 (en) 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
CN108472337B (en) 2015-08-03 2022-11-25 比奥贝拉蒂治疗公司 Factor IX fusion proteins and methods of making and using same
SG10201913278PA (en) 2016-02-01 2020-02-27 Bioverativ Therapeutics Inc Optimized factor viii genes
BR112019011115A2 (en) 2016-12-02 2019-10-01 Bioverativ Therapeutics Inc methods for treating hemophilic arthropathy using chimeric clotting factors
EP3576762A1 (en) 2017-01-31 2019-12-11 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
EP3665289A1 (en) 2017-08-09 2020-06-17 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
EP3687580A1 (en) 2017-09-27 2020-08-05 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
CA3108799A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (en) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
KR20220009389A (en) 2019-04-17 2022-01-24 코디악 바이오사이언시즈, 인크. Composition of exosomes and AAV
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0107278B1 (en) 1982-08-04 1989-11-15 National Research Development Corporation Molecular cloning of the gene for human anti-haemophilic factor ix
US5614500A (en) * 1983-03-04 1997-03-25 The Scripps Research Institute Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
US5171569A (en) * 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
DE3688983T2 (en) 1985-03-15 1994-02-17 British Tech Group Factor IX protein.
US4994371A (en) * 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2638643B1 (en) 1988-11-09 1991-04-12 Transgene Sa DNA SEQUENCE ENCODING HUMAN FACTOR IX OR AN ANALOGUE PROTEIN, EXPRESSION VECTOR, TRANSFORMED CELLS, PROCESS FOR PREPARING FACTOR IX, AND PRODUCTS OBTAINED THEREFROM
FR2650838A1 (en) * 1989-08-09 1991-02-15 Transgene Sa FACTOR IX EXPRESSION VECTORS IN A SUPERIOR EUKARYOTE CELL, PROCESS FOR THE PREPARATION OF FACTOR IX BY TRANSGENIC ANIMALS, AND FACTOR IX OBTAINED
SG48282A1 (en) * 1991-03-01 1998-04-17 Centeon Llc Preparation of factor ix
WO1994029471A1 (en) * 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
US5521010A (en) * 1994-03-25 1996-05-28 The Furukawa Electric Co., Ltd. Polyethylene for an insulation layer of a power cable and a crosslinked polyethylene insulated power cable using the same
DE4435520A1 (en) * 1994-10-04 1996-04-11 Immuno Ag Process for the separation of recombinant pro-factor IX from recombinant factor IX
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US6262242B1 (en) 1997-01-30 2001-07-17 Board Of Regents, The University Of Texas System Tumor suppressor designated TS10Q23.3
WO1998041240A1 (en) * 1997-03-14 1998-09-24 The Children's Hospital Of Philadelphia Methods and compositions for use in gene therapy for treatment of hemophilia
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin

Also Published As

Publication number Publication date
WO2002040544A2 (en) 2002-05-23
WO2002040544A9 (en) 2003-05-01
US20040110675A1 (en) 2004-06-10
WO2002040544A3 (en) 2002-10-31
US7125841B2 (en) 2006-10-24

Similar Documents

Publication Publication Date Title
AU2002226028A1 (en) Mutant human factor ix with an increased resistance to inhibition by heparin
AU2001260327A1 (en) Chair
AU2003281505A1 (en) Chair
AU7489900A (en) Music searching methods based on human perception
AU2003206949A1 (en) Venous prosthesis
AU2001251478A1 (en) Snack with improved flavor
AU2001285185A1 (en) Bearing with adjustable setting
AU2001265662A1 (en) Ergometer
AUPQ597500A0 (en) Improved theatre chair
AU2003263692A1 (en) Adjustable chair arrangement
AU2002246864A1 (en) Pim kinase-related methods
AU2003217336A1 (en) Current collectors
AU2001252200A1 (en) Chair
TW433413U (en) Hob screw structure
AU2001242742A1 (en) Copper-tolerant yeast and pectinase produced by the copper-tolerant yeast
AU2002248178A1 (en) Mutant cells with enhanced resistance to desiccation
AU2002231574A1 (en) Plants with improved resistance
AU2002224783A1 (en) Office chair
AU2002335232A1 (en) Long chair having massage function
AU2002215030A1 (en) Chair
AU2003214130A1 (en) Children's chair
AU2000226557A1 (en) Gliding run segment
AU2003238761A1 (en) An institutional deadbolt
AU2003284106A1 (en) Toy kitchen
AU7463401A (en) Can with sanitary lid-on